Clinical trials: Clinically Significant Prostate Cancer
Prostate Cancer
Prostate Imaging Using MRI +/- Contrast Enhancement
This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically…
- Trial name
- PRIME (NCT04571840)
- Testing
- Multiparametric MRI +/- prostate biopsy, Biparametric MRI +/- prostate biopsy
- Where
- 31 sites in United States, Argentina and 13 more
- Volunteers
- 500 people
- Sponsor
- University College, London
Prostate Cancer
Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION Trial
This study is an international multicentre RCT to compare the linically significant prostate cancer (csPCa) detection of cognitive-guided and MRI-USG guided biopsies in men with suspicious MRI lesion.
- Trial name
- NCT06303622
- Testing
- MRI-USG fusion approach, Cognitive-guided approach
- Where
- Hong Kong
- Volunteers
- 1,250 people
- Sponsor
- Chinese University of Hong Kong
Clinically Significant Prostate Cancer
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
- Trial name
- NCT07492927
- Where
- 10 sites in United States, China
- Volunteers
- 1,700 people
- Sponsor
- Xijing Hospital
Prostate Cancer
The TRANSLATE Trial
The TRANSLATE randomised controlled trial aims to evaluate local anaesthetic transperineal biopsy (LATP) versus transrectal ultrasound-guided (TRUS) prostate biopsy, in the evaluation of previously biopsy-naive men being…
- Trial name
- TRANSLATE (NCT05179694)
- Testing
- Prostate biopsy
- Where
- United Kingdom
- Volunteers
- 1,042 people
- Sponsor
- University of Oxford
Prostate Cancer
Targeted And Perilesional Or Systematic Biopsy In Prostate Cancer
Magnetic Resonance Imaging (MRI) improves the detection of clinically significant prostate cancer (PCa) by guiding biopsies of MRI-visible lesions (targeted biopsies) in patients suspected with having PCa.
- Trial name
- TARGET (NCT07296042)
- Testing
- Prostate biopsy
- Where
- 5 sites in France
- Volunteers
- 456 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Prostate Cancer
Artificial Intelligence Software (Prostate Intelligence) for Detecting Clinically Significant Prostate Cancer on MRI
The goal of this study is to learn how accurately an artificial intelligence (AI) software called Prostate Intelligence (Pi) detects clinically significant prostate cancer on prostate MRI in adults with a prostate gland who are…
- Trial name
- RADAR (NCT07875491)
- Testing
- AI-based prostate MRI analysis software
- Where
- Italy
- Volunteers
- 226 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer
Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision
The primary objective is to demonstrate non-inferiority of the detection rate of clinically significant prostate cancer (csPCa) in targeted biopsies based on PCaVision imaging (PCaVision pathway) in comparison with the detection…
- Trial name
- NCT06281769
- Testing
- 3D multi-parametric ultrasound targeted biopsy pathway using PcaVision, MRI targeted biopsy pathway
- Where
- 5 sites in Netherlands
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy
Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.
BIOPSTAGE is a prospective, non-randomized, diagnostic, multi-cohort investigational study to evaluate the impact of pelvic Multi-parametric 3-Tesla magnetic resonance imaging (mp-3TMRI) and whole-body 68Ga-PSMA PET/CT for…
- Conditions
- 68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy, Prostate Cancer, TNM Staging
- Trial name
- BIOPSTAGE (NCT03465579)
- Testing
- pelvic MRI, 68Ga-PSMA PET/CT
- Where
- 2 sites in Italy
- Volunteers
- 261 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS